Esperion Q4/FY23 revenue growth 72%/54%; litigation resolved with $100M payment; FDA PDUFA March 31

Esperion Therapeutics, Inc.

2023-FY EPS reported -$2.03 revenue$116,334,000

FY23 U.S. net product revenue $78.3M (+40% YoY); total revenue $116.3M (+54% YoY).
Q4 U.S. net product revenue $20.8M (+39% YoY); total revenue $32.3M (+72% YoY).
Litigation with DSE resolved; $100M received Jan 2024, additional $25M pending EMA label determination.
FDA PDUFA date March 31, 2024 for CV risk reduction label; Otsuka JNDA filing on track for 2024.
Cash position boosted by $90.8M net equity offering and $100M litigation payment; 2024 OpEx guidance $225-245M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Esperion Therapeutics, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue $32.3 million for the three months ended December 31, 2023, and $116.3 million for the full year ended December 31, 2023.

Period: fourth quarter and full year ended December 31, 2023
Revenue: $32.3 million for the three months ended December 31, 2023, and $116.3 million for the full year ended December 31, 2023
Result: reported results

Exact text from the filing

Esperion (NASDAQ: ESPR) today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.

View on SEC.gov

Browse all earnings releases →

Esperion Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-007035

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.